Sodium-Glucose Cotransporter 2 Inhibitors in Kidney Diseases Other Than That Due to Diabetes: Benefits in Composite Renal Outcomes Driven by Immunoglobulin A Nephropathy.
This research aims to evaluate the effects of sodium-glucose cotransporter 2 inhibitors on kidney diseases unrelated to diabetes.
Assessment of SGLT2 inhibitors in a population with chronic kidney disease.
Comparison of renal outcomes in patients with and without diabetes.
Focus on benefits attributed specifically to immunoglobulin A nephropathy.
SGLT2 inhibitors show positive effects on composite renal outcomes.
Benefits appear to be significantly influenced by immunoglobulin A nephropathy.
Improvements in kidney function noted across various patient groups, regardless of diabetes status.
Abstract
The overall benefit of SGLT2i in CKD due to causes other than diabetes, in patients with or without diabetes, may be predominantly driven by the benefits of IgAN.